AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab
A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with
Merck & Co has stated that the late-stage trials for its immunotherapy Keytruda to treat advanced melanoma has showed over half of the patients were alive two years after treatment had first began. The data gathered was part of multiple study results for its immunotherapy Keytruda in several cancer indications. Merck said the trial drug
